Abstract
This Clinical Practice Update provides revised guidance on the use of brexanolone and zuranolone in the postpartum period for depression that has onset in the third trimester or within 4 weeks postpartum. This document is a focused update of related content in Clinical Practice Guideline No. 5, Treatment and Management of Mental Health Conditions During Pregnancy and Postpartum (Obstet Gynecol 2023;141:1262–88) and replaces the August 2023 Practice Advisory, Zuranolone for the Treatment of Postpartum Depression.